Expertise in
1
conditions

Dr. Cynthia Brinson

Family Medicine
Office
900 E 30th St Ste 302, 
Austin, TX 
Offers Telehealth
Expertise in
1
conditions
Office
900 E 30th St Ste 302, 
Austin, TX 

Overview

Cynthia Brinson is a primary care provider, practicing in Family Medicine in Austin, Texas. Dr. Brinson is highly rated in 1 condition, according to our data. Her top areas of expertise are HIV/AIDS, Myelitis, AIDS Dysmorphic Syndrome, and AIDS Dementia Complex.

Her clinical research consists of co-authoring 43 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Family Medicine

Licenses

Family Medicine in TX

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Sendero
  • HMO
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
US Health and Life
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Office
900 E 30th St Ste 302, Austin, TX 78705

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants
Enrollment Status: Terminated
Publish Date: October 20, 2025
Intervention Type: Drug
Study Drug: Casirivimab+Imdevimab
Study Phase: Phase 3
A Phase IIb, Multicenter, Open-label, Rollover Study Evaluating the Efficacy, Safety and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months in HIV-1 Infected Adults Who Are Virologically Suppressed and Participated in Study LAI116482
A Phase IIb, Multicenter, Open-label, Rollover Study Evaluating the Efficacy, Safety and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months in HIV-1 Infected Adults Who Are Virologically Suppressed and Participated in Study LAI116482
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drugs: Long-acting cabotegravir, Long-acting rilpivirine, Rilpivirine, Dolutegravir
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir+Lamivudine, Tenofovir alafenamide based regimen
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
A Phase 3b Multi-center, Open Label, Single Arm, 52-week Study, Evaluating the Feasibility, Efficacy and Safety of Rapid Test and Treat Intervention in Newly Diagnosed HIV-1 Infected Adults Using a Fixed Dose Combination of Dolutegravir Plus Lamivudine (DOVATO) as a First Line Regimen
A Phase 3b Multi-center, Open Label, Single Arm, 52-week Study, Evaluating the Feasibility, Efficacy and Safety of Rapid Test and Treat Intervention in Newly Diagnosed HIV-1 Infected Adults Using a Fixed Dose Combination of Dolutegravir Plus Lamivudine (DOVATO) as a First Line Regimen
Enrollment Status: Completed
Publish Date: October 21, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

43 Total Publications

Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.
Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.
Journal: Annals of internal medicine
Published: December 22, 2025
Similar Doctors
Expertise in
139
conditions
Dr. Nimesh Patel
Family Medicine
Expertise in
139
conditions
Dr. Nimesh Patel
Family Medicine

Office

200 N Interstate 35 Ste 102, 
San Marcos, TX 
 (31.7 miles away)
737-214-1285
Languages Spoken:
English
See accepted insurances

Nimesh Patel is a primary care provider, practicing in Family Medicine in San Marcos, Texas. Dr. Patel is highly rated in 139 conditions, according to our data. His top areas of expertise are Tracheitis, H1N1 Influenza, Sinusitis, and Empyema.

Expertise in
186
conditions
Dr. Jeremy Wiseman
Family Medicine
Expertise in
186
conditions
Dr. Jeremy Wiseman
Family Medicine

Dr Richard J. Wiseman PA

2500 S Lakeline Blvd Ste 100, 
Cedar Park, TX 
 (16.0 miles away)
512-345-8970
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeremy Wiseman is a primary care provider, practicing in Family Medicine in Cedar Park, Texas. Dr. Wiseman is highly rated in 186 conditions, according to our data. His top areas of expertise are Obesity in Children, Hypothyroidism, Hashimoto Thyroiditis, and Male Pseudohermaphroditism with Gynecomastia.

Expertise in
28
conditions
Dr. Paul Cauvin
Family Medicine
Expertise in
28
conditions
Dr. Paul Cauvin
Family Medicine

Austin Regional Clinic PA

6835 Austin Center Blvd, 
Austin, TX 
 (4.6 miles away)
512-346-6611
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Paul Cauvin is a primary care provider, practicing in Family Medicine in Austin, Texas. Dr. Cauvin is highly rated in 28 conditions, according to our data. His top areas of expertise are Parinaud Oculoglandular Syndrome, Cellulitis, Tracheitis, and Multisystem Inflammatory Syndrome in Children (MIS-C).

Frequently Asked Questions about Dr. Cynthia Brinson

How do I make an appointment with Dr. Cynthia Brinson?

You can book an appointment with Dr. Cynthia Brinson by calling their office at 512-476-6555. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Cynthia Brinson a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Cynthia Brinson is classified as an Distinguished expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Cynthia Brinson specialize in?

While Dr. Cynthia Brinson is a Family Medicine, they have specific expertise in HIV/AIDS, Myelitis, and AIDS Dysmorphic Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Family Medicine.

Does Dr. Cynthia Brinson participate in research or clinical trials?

Yes. Dr. Cynthia Brinson has published 43 articles and abstracts on conditions like HIV/AIDS. You can view a list of Dr. Cynthia Brinson's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Cynthia Brinson accept my insurance?

Dr. Cynthia Brinson accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 512-476-6555 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Brinson's expertise for a condition
ConditionClose
      View All 11 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile